Komunikaty prasowe są wydawane przez FUJIFILM Corporation w Japonii.
Fujifilm nie gwarantuje, że produkty w tych komunikatach prasowych są dostępne w sprzedaży we wszystkich krajach i regionach.
Należy pamiętać, że zawartość tej witryny internetowej jest aktualna w dniu ogłoszenia prasowego i może ulec zmianie bez wcześniejszego powiadomienia. Informacje w każdym komunikacie, w tym o dostępności produktu, specyfikacji, cenach i kontaktach, są ważne w momencie publikacji.
- Kw. 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Lut. 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Gru. 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Lis. 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Cze. 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mar. 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Gru. 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Gru. 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Paź. 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan
- Cze. 30, 2022
- Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
- Kw. 5, 2022
- Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Mar. 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product - Sty. 26, 2022
- Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
- Wrz. 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Sie. 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Cze. 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Cze. 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical)